CMS: Data shows moderate support for Provenge use

All of the available data for Dendreon's Provenge prostate cancer vaccine shows 'moderate' support for its use, according to a government analysis. CMS, which meets with outside advisers next Wednesday to discuss paying for the vaccine, analyzed all the available evidence for the therapy that has had drawn scrutiny for its large price tag amid praise from cancer advocates. Company shares, which closed at $34.83, rose 5.4 percent to $36.70 in after-hours trading. Also, Dendreon says it has applied for FDA approval to essentially quadruple the capacity of its New Jersey factory. Story | News

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.